Gastric Ulcers, Duodenal Ulcers, Gastric Ulcers Perforation, and Duodenal Ulcers Perforation: A Comprehensive Guide and Glasgow-Blatchford Score Link GU and DU to UGIH

Introduction:

Peptic ulcer disease (PUD), characterized by mucosal breaks in the stomach (gastric ulcer) or duodenum (duodenal ulcer), remains a common and potentially serious gastrointestinal condition. While often straightforward in presentation, the management of PUD requires a nuanced understanding of its diverse etiologies, pathophysiology, and clinical manifestations. This review delves deeper into these complexities, offering a comprehensive guide for the seasoned gastroenterologist navigating the diagnostic and therapeutic challenges of gastric and duodenal ulcers.

---

I. Etiology and Pathophysiology: Unveiling the Underlying Mechanisms

A. Gastric Ulcer:

1. Etiology: A Multifaceted Landscape:

• Helicobacter pylori Infection: The leading cause of gastric ulcers worldwide.
  • Geographic Variability: Prevalence and strain virulence vary significantly across regions, impacting local ulcer risk.
  • Virulence Factors: CagA and VacA positivity is associated with increased ulcer risk and severity.
  • Antibiotic Resistance: A growing concern necessitates tailoring eradication regimens based on local resistance patterns.
• NSAID Use: A major contributing factor, particularly in older adults.
  • Underlying Risk Factors: Age >65, prior ulcer history, concurrent corticosteroid or anticoagulant use, H. pylori co-infection all increase the risk.
  • COX-2 Selective Inhibitors: While associated with a lower risk compared to traditional NSAIDs, ulcer risk is not completely eliminated.
• Less Common Causes:
  • Inflammatory Bowel Disease (Crohn's disease), sarcoidosis, vascular insufficiency (atherosclerosis, vasculitis), gastric lymphoma (can mimic refractory ulcers).

2. Pathophysiology: A Delicate Balance Disrupted:

• Disrupted Mucosal Defenses:
  • Gastric ulcers arise from an imbalance between aggressive factors (gastric acid, pepsin) and protective mucosal defense mechanisms.
  • H. pylori directly disrupts these defenses by:
    • Inducing chronic inflammation.
    • Disrupting the mucus-bicarbonate barrier.
    • Reducing mucosal blood flow.
    • Inhibiting prostaglandin synthesis.
  • NSAIDs contribute to ulcer development by:
    • Direct mucosal damage.
    • Reducing prostaglandin synthesis, vital for mucosal protection and repair.
• Delayed Gastric Emptying:
  • While less common than in duodenal ulcers, delayed gastric emptying can exacerbate acid exposure in the stomach, potentially contributing to ulcer formation or refractoriness to treatment.

B. Duodenal Ulcer:

1. Etiology: The Primacy of Acid:

• Helicobacter pylori Infection: Remains the most common cause of duodenal ulcers.
  • Geographic Variations: Similar to gastric ulcers, H. pylori prevalence and strain virulence influence ulcer risk in different regions.
• Hypergastrinemia: Excess gastrin drives acid hypersecretion.
  • Thorough Investigation: Measure fasting serum gastrin levels. Levels >1000 pg/mL are highly suggestive of Zollinger-Ellison syndrome (ZES).
  • Consider ZES: In patients with multiple ulcers, refractory ulcers, prominent diarrhea, or a family history of endocrine neoplasia.
• Genetic Predisposition:
  • Individuals with blood group O, non-secretors of blood group antigens, or a positive family history are at increased risk.

2. Pathophysiology: Excess Acid and Vulnerable Mucosa:

• Excess Gastric Acid Secretion:
  • Often due to increased parietal cell mass (the acid-producing cells in the stomach) and a heightened response to stimuli like food or gastrin.
• Rapid Gastric Emptying:
  • Delivers a large volume of highly acidic gastric contents into the duodenum, overwhelming its defenses.
• Impaired Duodenal Mucosal Defenses:
  • The duodenal mucosa is inherently less robust compared to the gastric mucosa.
  • Protective factors: Bicarbonate secretion, epidermal growth factor, nitric oxide.
• Bile Reflux:
  • Bile reflux from the duodenum into the stomach can disrupt gastric mucosal defenses, contributing to ulcer formation, particularly in the proximal duodenum.
  • Consider in patients with prior biliary surgery or structural abnormalities affecting the pylorus.

---

II. Clinical Presentation: Beyond the Textbook Case

• Typical Symptoms:
  • Gastric Ulcer:
    • Epigastric pain typically worsens with meals.
    • Nausea, vomiting, bloating, early satiety, and weight loss may also occur.
  • Duodenal Ulcer:
    • Classically presents with epigastric pain that occurs 2-3 hours after meals or at night, often relieved by food or antacids.
    • Nausea, vomiting, bloating, and early satiety may be present.
• Atypical Presentations: Maintain a high index of suspicion in high-risk groups.
  • Elderly Patients: May have minimal or atypical symptoms, including painless bleeding.
  • Chronic NSAID or Corticosteroid Use: May mask typical ulcer symptoms.
  • Significant Comorbidities (Diabetes, Renal Insufficiency): May alter the clinical presentation.
  • High Suspicion for Complications: These groups warrant close monitoring for complications like bleeding or perforation, even with minimal symptoms.
• Alarming Symptoms: Red flags demanding prompt and thorough investigation:
  • Significant weight loss: Unexplained weight loss raises concern for malignancy.
  • Persistent vomiting: Suggests gastric outlet obstruction.
  • Dysphagia: Difficulty swallowing may indicate a stricture or mass.
  • Iron Deficiency Anemia: Low hemoglobin (< 12 g/dL in women, < 13 g/dL in men) in the absence of other explanations suggests chronic blood loss.
  • Family History of Gastric Cancer: Increases the risk of malignancy, especially in patients with gastric ulcers.

---

---

III. Diagnosis: A Systematic and Precise Approach

A. History and Physical Examination: The foundation for diagnosis and risk assessment.

• Thorough History:
  • Elicit a detailed history of:
    • Symptoms: Onset, location, character, radiation, aggravating/relieving factors.
    • Medications: Especially NSAID use, aspirin, corticosteroids, anticoagulants.
    • Past medical history: Prior ulcers, gastrointestinal surgeries, H. pylori infection, other comorbidities.
    • Family history: Gastric cancer, PUD.
    • Social history: Smoking, alcohol use.
• Physical Examination:
  • Assess for:
    • Epigastric tenderness: Location and severity.
    • Signs of complications: Bleeding (hematemesis, melena, hematochezia), perforation (abdominal rigidity, guarding, rebound tenderness, peritoneal signs), obstruction (abdominal distension, succussion splash).

B. Upper Endoscopy (Gold Standard): Direct visualization is essential.

• Visualizing the Ulcer:
  • Meticulously describe the following:
    • Location: Gastric vs. duodenal, anterior/posterior wall, greater/lesser curvature.
    • Size: Measure in millimeters.
    • Shape: Round, oval, linear, irregular.
    • Edges: Regular vs. irregular, raised/flattened, undermined.
    • Base: Clean, white, fibrinous, pigmented (hematin - black/brown).
    • Surrounding mucosa: Erythema, edema, scarring, fold thickening, nodularity.
• Biopsy (Mandatory): Obtain multiple biopsies to:
  • Test for H. pylori: At least 2 biopsies from the ulcer margin.
  • Rule out malignancy: Particularly important for gastric ulcers, 4-8 biopsies depending on ulcer size and characteristics, including biopsies from any suspicious areas (nodularity, irregular edges).

C. H. pylori Testing: Confirming the presence or absence of infection is crucial.

• Endoscopic Testing (During Endoscopy):
  • Rapid urease test: Provides a rapid result but can be affected by PPI use.
  • Histology: The gold standard for diagnosis, but results may take longer.
• Non-Invasive Testing:
  • Urea breath test: Highly accurate if performed correctly.
  • Stool antigen test: Another reliable option.
• Confirming Eradication:
  • Perform a urea breath test or stool antigen test at least 4 weeks after completing H. pylori eradication therapy to ensure successful treatment.

D. Laboratory Investigations: Aids in assessing severity and complications.

• Complete Blood Count (CBC):
  • Hemoglobin (Hgb) and Hematocrit (Hct): Assess for anemia, indicating the severity of bleeding.
  • Platelet count: Low platelets can increase bleeding risk.
• Basic Metabolic Panel (BMP):
  • Electrolytes: Evaluate for imbalances, particularly hypokalemia and hypochloremia, common with vomiting.
  • Renal function: BUN and creatinine assess kidney function, important for medication dosing and complications.

E. Imaging Studies: Used selectively to evaluate complications.

• Upright Chest X-ray:
  • Indicated if perforation is suspected.
  • Finding: Free air under the diaphragm (crescent sign) is highly suggestive of perforation.
• Abdominal CT Scan:
  • More sensitive for perforation, assesses severity, and can reveal extraluminal air or fluid collections.
• Upper GI Series (Barium Swallow):
  • Helpful for evaluating gastric outlet obstruction.
  • Findings: Delayed gastric emptying, narrowing of the pyloric channel.

F. Understanding the Glasgow-Blatchford Score (GBS):

The GBS is a risk stratification tool used to assess the severity of UGIH and predict the likelihood of needing intervention (such as blood transfusions or endoscopic therapy) or death. It is particularly valuable in the emergency department setting to help guide initial management decisions.

Key Features:

• Based on Clinical and Laboratory Parameters: The score incorporates readily available information, making it quick and easy to calculate at the bedside.
• Prioritizes Sensitivity: The GBS is designed to be highly sensitive, aiming to minimize false negatives (missing patients who actually require intervention). A low GBS is therefore very reassuring, suggesting a low risk of adverse outcomes.
• Limited Specificity: The GBS has lower specificity, meaning it may overestimate risk in some patients who ultimately do not require intervention. This is a trade-off for its high sensitivity.

How to Use the GBS:

• Calculate the Score: Add the points for each risk factor present at admission.
• Interpret the Score:
  • GBS of 0: Very low risk; safe for outpatient management if other clinical factors permit.
  • GBS of 1: Very low risk; strong consideration for outpatient management if other clinical factors permit (shared decision-making is crucial here).
  • GBS ≥ 2: Increased risk; generally warrants hospital admission for closer monitoring and potential intervention.

Glasgow-Blatchford Score Table:

Teaching Points:

• BUN Elevation: Reflects hypovolemia (dehydration) from blood loss.
• Anemia Severity: Lower hemoglobin indicates more significant bleeding.
• Hypotension: A sign of hemodynamic instability.
• Tachycardia: A compensatory response to blood loss.
• Melena: Suggests upper GI source of bleeding.
• Syncope: Indicates significant blood loss and potential hypovolemia.
• Hepatic Disease & Cardiac Failure: Increase the risk of poor outcomes from UGIH.

Clinical Judgment is Crucial:

The GBS is a tool to assist clinical judgment, not replace it. Consider the following:

• Patient History: Prior ulcers, medications, comorbidities.
• Clinical Status: Hemodynamic stability, ongoing bleeding signs, level of concern.
• Resources: Availability of endoscopy, blood transfusions, etc.

By combining the GBS with a thorough clinical assessment, informed decisions about the most appropriate management for patients presenting with UGIH can be made.

---

IV. Management: A Personalized Approach to Healing and Prevention

A. Goals of Therapy:

1. Relieve symptoms: Prompt pain control is essential.
2. Promote ulcer healing: Address underlying causes and optimize the gastric environment.
3. Prevent recurrence: Eradicate H. pylori, manage NSAID use, and address other risk factors.
4. Manage complications: Recognize and treat bleeding, perforation, and obstruction.

B. Risk Stratification: Tailoring Treatment to the Individual:

• Individualize management based on:
• Age: Elderly patients have increased complication risks.
• Comorbidities: Diabetes, cardiovascular disease, and renal insufficiency impact prognosis and treatment choices.
• Ulcer location and size: Gastric ulcers require more cautious management due to malignancy risk.
• H. pylori status: Eradication is crucial for preventing recurrence.
• NSAID use: Discontinuation or careful management is necessary.
• Bleeding risk: Assess using clinical factors and the GBS.

C. Lifestyle Modifications: Empowering Patients for Long-Term Success:

• Smoking Cessation:
  • Absolutely essential for ulcer healing, reducing recurrence, and improving overall health.
  • Provide resources, counseling, and support for smoking cessation.
• Alcohol Moderation:
  • Limit or avoid alcohol intake, as it can irritate the gastric mucosa and delay healing.
• Dietary Changes:
  • No specific "ulcer diet" exists, but advise patients to avoid trigger foods that worsen their symptoms (individualized).
  • Encourage regular, small meals rather than large, infrequent meals.

D. Pharmacotherapy: Targeting Acid, Healing, and Eradication

1. H. pylori Eradication (if Present):

• First-Line Therapy (10-14 Days):
  • Triple Therapy: antibiotic 2/3
  • PPI: Standard dose (e.g., omeprazole 20mg twice daily).
  • Clarithromycin: 500mg twice daily. (or metronidazole 500mg twice daily if Clarithromycin is unavailable).
  • Amoxicillin: 1g twice daily (or metronidazole 500mg twice daily if penicillin allergic).
• Second-Line Therapy (10-14 Days):
  • If first-line therapy fails, consider culture-guided antibiotic selection or bismuth-containing quadruple therapy. readmore

2. Acid Suppression: Cornerstone of ulcer treatment.

• Proton Pump Inhibitors (PPIs): The most effective agents for acid suppression.
  • Standard Doses:
    • Omeprazole: 20-40mg once or twice daily.
    • Lansoprazole: 30mg once or twice daily.
    • Esomeprazole: 40mg once or twice daily.
    • Pantoprazole: 40mg once or twice daily.
    • Rabeprazole: 20mg once or twice daily.
  • Twice-daily Dosing: Consider for refractory cases, nocturnal acid breakthroughs, or interactions with medications that affect PPI metabolism.
  • More Potent PPI: If standard-dose PPIs are ineffective, consider switching to a more potent PPI or increasing the dose.
• H2 Receptor Antagonists: Less potent than PPIs, used as adjunctive therapy or in specific situations (e.g., mild symptoms, cost concerns).
  • Ranitidine, famotidine, cimetidine (use with caution due to drug interactions).
• Mucosal Protectants: Offer additional protection to the ulcerated mucosa.
  • Sucralfate: 1g four times daily (before meals and at bedtime), creates a protective barrier over the ulcer.
  • Bismuth subsalicylate: Various formulations available, have both anti-inflammatory and antimicrobial effects.

E. Endoscopic Therapy: For Active Bleeding or High-Risk Lesions

• Indications:
  • Active bleeding: Spurting, oozing, or non-bleeding visible vessels.
  • High-risk stigmata of recent hemorrhage: Adherent clot, non-bleeding visible vessel.
• Endoscopic Techniques:
  • Injection Therapy:
    • Epinephrine (1:10,000 dilution): 0.5-2.0mL aliquots, injected around the bleeding point to induce vasoconstriction. Always use in combination with another modality.
    • Sclerosants (e.g., absolute ethanol): 0.1-0.2mL aliquots injected into the ulcer base, causing tissue necrosis and hemostasis (maximum total dose: 1-2mL).
  • Thermal Therapy:
    • Heater probe: Delivers controlled heat to coagulate bleeding vessels (30-70 J applications).
    • Bipolar electrocoagulation: Uses electric current to coagulate bleeding vessels (15-20 W for 8-10 seconds).
  • Clipping: Hemoclips are placed across the bleeding point and at the ulcer margins to stop bleeding mechanically.

F. Surgery: A Last Resort for Complications

• Indications:
  • Perforation: A surgical emergency requiring prompt repair.
  • Uncontrolled bleeding: When endoscopic therapy fails to achieve hemostasis.
  • Gastric outlet obstruction: When conservative measures (e.g., nasogastric decompression, IV fluids) are ineffective.
• Surgical Procedures:
  • Ulcer repair: Direct closure of the perforation.
  • Omental patch repair: Uses a piece of omentum (fatty tissue from the abdomen) to reinforce the closure.
  • Partial gastrectomy: Removal of part of the stomach, usually indicated for large or complex ulcers, uncontrolled bleeding, or obstruction.

---

V. Gastric and Duodenal Ulcer Perforation: Prompt Recognition and Action

A. Pathophysiology:

• Erosion of the ulcer through all layers of the stomach or duodenum.
• Spillage of gastric contents into the peritoneal cavity, leading to peritonitis (inflammation of the abdominal lining).

B. Clinical Presentation: A classic surgical abdomen.

• Sudden onset of severe, unrelenting epigastric pain: Often radiating to the back or shoulders.
• Abdominal rigidity: A board-like abdomen due to involuntary muscle spasm.
• Guarding: Pain worsens with palpation.
• Rebound tenderness: Pain increases when pressure is released from the abdomen.
• Signs of peritonitis and sepsis: Fever, tachycardia, hypotension, altered mental status.

C. Diagnosis: Clinical and Radiographic Confirmation

• Clinical suspicion: Based on the characteristic presentation.
• Imaging studies are crucial for confirmation:
• Upright chest X-ray: Reveals free air under the diaphragm (crescent sign).
• Abdominal CT scan: Confirms the perforation and assesses severity, showing extraluminal air or fluid.

D. Management: A Surgical Emergency

• Immediate hospitalization and aggressive intervention are required.
• Resuscitation:
• Intravenous fluids to combat hypovolemia.
• Broad-spectrum antibiotics to treat peritonitis.
• Nasogastric decompression to remove gastric contents and decompress the stomach.
• Definitive Treatment: Urgent surgery is the definitive treatment.
• Primary closure of the perforation: The most common approach.
• Omental patch repair: Reinforces the closure, particularly for large or friable perforations.
• Partial gastrectomy: May be necessary for large, complex perforations, uncontrolled bleeding, or obstruction.

---

VI. Prognosis and Follow-up: A Lifelong Approach to Management

• Ulcer Healing: Most ulcers heal with appropriate medical therapy.
• Recurrence Risk:
• Common, especially if H. pylori is not eradicated or NSAID use continues.
• Educate patients about recurrence risk and the importance of adhering to treatment.
• Follow-up: Long-term care is crucial.
• Monitor H. pylori eradication: Repeat urea breath test or stool antigen test 4 weeks after completing therapy.
• Assess ulcer healing: Consider repeat endoscopy if symptoms persist or if initial ulcer characteristics were concerning.
• Long-Term Management:
• PPI therapy duration: Tailor duration based on individual risk factors, balancing benefits and potential risks of long-term PPI use.
• Endoscopic surveillance for gastric ulcers: Consider surveillance endoscopy for gastric ulcers with concerning features or in patients with risk factors for gastric cancer.
• Periodic H. pylori re-testing: Consider re-testing in patients with a history of infection, especially if they have recurrent ulcers or continue to be exposed to risk factors.

---

Conclusion: PUD is a common but multifaceted condition requiring a deep understanding of its diverse etiologies, pathophysiology, and potential complications. Gastroenterologists can effectively manage this condition, minimize recurrence, and optimize long-term patient outcomes by employing a meticulous and individualized approach to diagnosis, risk stratification, and treatment. Continuous education and staying abreast of the latest advancements in the field are essential for providing the best possible care for those living with PUD.